Form 8-K - Current report:
SEC Accession No. 0001641172-25-020520
Filing Date
2025-07-22
Accepted
2025-07-22 08:05:33
Documents
15
Period of Report
2025-07-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38000
2 EX-5.1 ex5-1.htm EX-5.1 12482
3 GRAPHIC ex5-1_001.jpg GRAPHIC 11161
4 GRAPHIC ex5-1_002.jpg GRAPHIC 10893
  Complete submission text file 0001641172-25-020520.txt   249829

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE imnn-20250722.xsd EX-101.SCH 3008
6 XBRL LABEL FILE imnn-20250722_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE imnn-20250722_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3688
Mailing Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648
Business Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648 (609) 896-9100
Imunon, Inc. (Filer) CIK: 0000749647 (see all company filings)

EIN.: 521256615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-15911 | Film No.: 251138714
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)